Hanmi to Present Phase 2 Data of EPeglucoagon (HM15136) for CHI at ESPE 2026
Hanmi Pharmaceutical will unveil Phase 2 results of EPeglucoagon (HM15136), the first weekly‑dose therapy for congenital hyperinsulinism, at the ESPE 2026 meeting in Marseille.